The company is outgrowing its own explanations: management keeps telling investors the reported numbers are not the busi
The model's full reasoning — Q3 2023 call → NOWe need to determine if management conveys that the reported results for the period do not represent the business as it is actually running today. The call is for Q3 2023. Management discusses progress in Phase III trials, financing, and other developments. They mention that the Phase III trials are on track, with primary endpoint readouts in summer 2024 and mid-2025. They also discuss the August financing that extended cash runway. They talk about site initiations and patient demand. They mention that the Q3 results reflect continued success in advancing trials and the financing. They also note that cash used in operations was higher due to R&D tax credit not yet received, but expected in Q4. They provide guidance for Q4 and full year. They discuss pre-commercial work and infrastructure. They mention the new CPT code effective January 2024. They talk about the PTSD study fully recruited with top-line readout this year. They discuss anorexia trial modifications. The question is whether management indicates that the reported period is stale relative to the operating present. That is, the business as it stands today is ahead of the business as it appears in the reported period. Management does mention that the Q3 results include the financing and progress, but they don't explicitly say that the reported numbers understate the current business. They talk about ongoing progress and future milestones. They mention that the financing extends runway into late 2025, which is forward-looking. They talk about site initiations continuing to grow, but that's part of the ongoing trials. They don't say that the reported period missed something that is now happening. They do mention that the R&D tax credit is expected in Q4, but that's a timing issue. They also mention that the PTSD data will be read out this year, but that's future. They don't say that the reported period is not representative of the current business. They are just reporting results and giving guidance. The call seems like a standard results and outlook discussion. There is no indication that the reported numbers are stale relative to the present. Management is not drawing attention to a gap between the reported period and the current business. They are just updating on progress. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
VRE · Q4 2022 → YESThe question is: Does management convey that the reported results for the period do not represent the business the company is actually running today? That the just-reported numbers describe a company ...YES The transcript shows management repeatedly framing the reported period as transitional and not reflective of the current business: the shift to a pure-play multi-family company has already reduced office and hotel exposure while driving multi-family NOI share to 98%, with Haus25 leased at 95% ahead of schedule and same-store NOI guidance of 4-6% for 2023. They explicitly note that earnings variability stems from the ongoing asset sales and reallocation, with the business now positioned for growth as the transformation concludes, and they highlight post-period activity like additional sales and stabilized properties to underscore that the reported numbers capture a pre-transition state.
PFE · Q4 2023 → YESThe question is: Does management convey that the reported results do not represent the business the company is actually running today? That the just-reported numbers describe a company that has alread...NO The transcript shows management framing 2023 results as a challenging year with declines driven by COVID products, while positioning 2024 as a year of execution and growth through new priorities like the Seagen acquisition (closed late in 2023 with minimal contribution) and new product launches. This is a standard results-and 2024 outlook discussion, with forward-looking elements on pipeline, margins, and capital allocation rather than indicating the reported period is stale relative to current operations.
PRIM · Q2 2018 → YESThe question is whether management conveys that the reported results for Q2 2018 do not represent the business the company is actually running today. Specifically, if the printed period is stale relat...YES The transcript shows management repeatedly framing the Q2 results as a partial picture due to the late June 1 acquisition of Willbros. They note the business is "running as planned," highlight one-month revenue contribution of $1.